Emerging in the arena of obesity treatment, retatrutide presents a unique strategy. Unlike many existing medications, retatrutide works as a twin agonist, simultaneously engaging both glucagon-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic hormone (GIP) receptors. This concurrent engagement encourages several advantageous effects, like… Read More